The stock will move on merger execution, not quarterly results. Monitor for regulatory and stockholder approvals for the Eos merger; failure to close would likely lead to cash depletion and delisting risk. The $1M preferred placement provides a short cash runway.
Price Chart
Executive Summary
Pulmatrix reported Q1 2026 results with no revenue and a net loss of $1.2M, improved from $1.8M a year ago. Cash stood at $3.3M with a going-concern qualification. The company is pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, having raised $1M in a private placement. This is a minimal-event filing for a pre-revenue entity reliant on merger completion.
Key Financial Metrics
Key Facts
- Net loss of $1.2M for Q1 2026 vs $1.8M in Q1 2025, improvement of 35%
- Cash and equivalents of $3.3M as of March 31, 2026, down from $4.1M at year-end 2025
- Financial statements prepared on a going-concern basis
- All clinical development on hold while seeking to license or monetize assets
- Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026
- Raised $1M gross proceeds from private placement of Series B Convertible Preferred Stock
Financial Impact
Net loss improved to $1.2M from $1.8M; no revenue. Cash burn of ~$0.8M during the quarter.
Risk Factors
- Merger with Eos may not close, leaving the company without a viable path forward
- Cash of $3.3M is insufficient for long-term operations without additional funding or deal completion
- Ongoing going-concern qualification increases bankruptcy risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023367 |
| Document: form8-k.htm | 0001493152-26-023367 |
| Document: 0001493152-26-023367-index-headers.html | 0001493152-26-023367 |
| Document: 0001493152-26-023367-index.html | 0001493152-26-023367 |
| Document: 0001493152-26-023367.txt | 0001493152-26-023367 |
| 8-K Data (Synthetic) | 0001493152-26-023367 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | S-4/A | $1.40 $1.45 | ▼ −3.58% | ▼ −4.70% | $1.57 (−12.54%) |
Aug 13, 2026 7w ago | 8-K | $1.51 $1.50 | ▼ −0.66% | ▲ +1.30% | $1.57 (+3.97%) |
Aug 13, 2026 7w ago | Press Release | $1.51 $1.50 | ▲ +0.66% | ▼ −1.30% | $1.57 (−3.97%) |
Aug 7, 2026 8w ago | S-3/A | $1.57 $1.56 | ▲ +0.64% | ▲ +0.59% | $1.57 (−0.00%) |
Jun 16, 2026 15w ago | 10-K/A | $1.50 $1.53 | ▲ +2.00% | ▲ +3.04% | $1.57 (+4.67%) |
Jun 5, 2026 17w ago | 425 | $1.33 $1.40 | ▲ +5.26% | ▲ +4.69% | $1.57 (+18.05%) |
Jun 4, 2026 17w ago | S-3 | $1.32 $1.38 | ▼ −4.55% | ▼ −7.10% | $1.57 (−18.94%) |
May 15, 2026 20w ago | 8-K | $1.25 $1.34 | ▲ +7.20% | ▲ +6.24% | $1.57 (+25.60%) |
Apr 21, 2026 23w ago | 8-K | $1.38 $1.28 | ▼ −7.25% | ▼ −8.33% | $1.57 (+13.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access